Trials / Recruiting
RecruitingNCT06688188
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.
Detailed description
C-X-C motif chemokine receptor 4 (CXCR4) is highly expressed in patients affected with malignant tumors and ex-vivo analyses provided evidence that the expression level on the tumor cell surface is tightly linked to the proliferation index. In recent years, the diagnostic PET agent 68Ga-Pentixafor targeting this chemokine receptor has been extensively validated in haematological malignancies and solid tumors. 68Ga-JH12, a novel radiopharmaceutical targeting CXCR4, demostrated high stability in vitro and in vivo, and can accumulate specifically in tumors with high binding affinity, safety, and selectivity in preclinical studies. In this study, the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with Various Cancers were observed to evaluate the dosimetric characteristics of 68Ga-JH12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-JH12 | The dose will be 148-222 MBq given intravenously. |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-06-30
- Completion
- 2025-12-31
- First posted
- 2024-11-14
- Last updated
- 2024-11-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06688188. Inclusion in this directory is not an endorsement.